Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: radman33 who wrote (535)	2/10/1999 1:03:00 PM
From: Anthony Wong	Respond to of 942

Jay, my understanding is that they get to co-market one of Pfizer's drug, but then you may be right. We really don't know details about their agreement.

To: radman33 who wrote (535)	2/17/1999 2:12:00 PM
From: Anthony Wong	Respond to of 942

Lipitor Approved In Canada For Three New Indications February 17, 1999 TORONTO, ON. -- Health Canada has approved three new indications for Parke-Davis' and Pfizer Canada Inc.'s cholesterol-lowering drug Lipitor(R)(atorvastatin calcium) to include use as an adjunct to diet for the following conditions: dysbetalipoproteinemia (Type III); hypertriglyceridemia (Type IV); and homozygous familial hypercholesterolemia (as an adjunct to LDL apheresis if available, otherwise as monotherapy). Lipitor is also indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia. The recommended starting dose of Lipitor is 10mg once daily. The dosage range is 10 to 80 mg once daily. Lipitor has been shown in clinical studies to produce reductions in LDL-cholesterol in patients with elevated cholesterol of 39 percent to 60 percent across the dose range of 10 to 80 mg. Reductions in triglycerides of 19 percent to 37 percent were reported in clinical trials in patients with mild to moderate hypercholesterolemia across the same dose range. Furthermore, in clinical trials with Lipitor (10 to 80 mg) in patients with hypertriglyceridemia show further reductions of triglycerides by 25 to 56 percent. Lipitor is generally well tolerated. Adverse reactions are similar to other statins and have usually been mild and transient, with fewer than two percent of patients being discontinued from clinical trials due to side effects related to Lipitor. This rate of discontinuation was comparable to that of placebo. The most frequent adverse events of atorvastatin reported during clinical trials are constipation, flatulence and dyspepsia. It is recommended that liver functions tests be performed prior to initiating therapy and periodically thereafter. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of creatine phosphokinase, which may be more frequent when co-administered with drugs that inhibit the cytochrome P-450 metabolising enzyme system. pslgroup.com